VivoSeq
Other

Urinary Incontinence

29

Pipeline Programs↗

13

Active Trials↗

15

Companies Involved↗

Urinary incontinence is an emerging landscape with 29 programs across 15 companies. The most active players are Viatris Specialty LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sanofi. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

22/100

Mech. Concentration

15/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

Phase 2Sanofi logo

Sanofi

1 program

Phase 2U

UroGen Pharma Ltd.

1 program

Phase 2GSK logo

GSK

1 program

Phase 3V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

31 of 34 classified programs — the dominant modality here.

9%ALL OTHERSCell therapy26%Protein / enzyme13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.

Analysis

Trial Status

67

clinical trials

Completed43 · 64%
Recruiting7 · 10%
Unknown status6 · 9%
Active, not recruiting4 · 6%
Terminated3 · 4%
Withdrawn2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

67 trials

Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old
Recruiting·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 1·NCT06738576·60 enrolled
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
Recruiting·UUniversity of Aarhus·Phase 3·NCT06551246·236 enrolled
Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
Recruiting·UUniversity of Aarhus·Phase 4·NCT06465576·216 enrolled
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT04565925·24 enrolled
An Open-label Pilot Study Conducted in the UK to Evaluate the Clinical Benefits of the PureWick™ Female External Catheter System Compared to Indwelling Urinary Catheters in Female Patients Receiving Home-based Care
Recruiting·BBecton, Dickinson and Company·N/A·NCT07555548·95 enrolled
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
Recruiting·MMedtronicNeuro·Preclinical·NCT07456865·256 enrolled
Prospective and Comparative Evaluation of a Medical Device Composed of a Perineal Probe Connected to a Mobile Application in the Management of Stress Urinary Incontinence.
Recruiting·NNantes University Hospital·Preclinical·NCT06285292·138 enrolled
Assessment of Platelet Rich Plasma Injection in Managing Female Patients Complaining of Mixed Urinary Incontinence (PRP)
Active, not recruiting·ZZagazig University·N/A·NCT06769074·24 enrolled
Use of Sildenafil for Treatment of Urinary Incontinence
Active, not recruiting·TThe University of Texas Medical Branch, Galveston·Phase 1·NCT02983461·24 enrolled
Effect of Extracorporeal Magnetic Stimulation Added to Pelvic Floor Muscle Training on Post-Prostatectomy Urine Incontinence: A Prospective Randomized Controlled Trial
Active, not recruiting·TTanta University·Preclinical·NCT07698028·100 enrolled
Impact of Urinary Incontinence on Quality of Life and Daily Activities in Women: A Cross-Sectional Comparison Between Urban and Rural Areas
Active, not recruiting·Lokman Hekim University·N/A·NCT07669922·100 enrolled
Autologous Muscle Stem Cell Therapy for Treatment of Congenital Urinary Incontinence in Epispadias Patients
Not yet recruiting·SSimone Spuler, MD·Phase 1/2·NCT04729582·21 enrolled
The Effect of High-frequency Laser Therapy and Pelvic Floor Muscle Training in Women With Stress Urinary Incontinence: A Plasebo Randomized Controlled Trial
Enrolling by invitation·NNecmettin Erbakan University·Preclinical·NCT07319247·36 enrolled
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269750·100 enrolled
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
Completed·FFemmePharma Global Healthcare, Inc.·Phase 2·NCT00749632·45 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)